Supernus Pharmaceuticals Inc [SUPN] stock is trading at $31.17, down -0.67%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SUPN shares have lost -2.04% over the last week, with a monthly amount drifted -19.35%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Supernus Pharmaceuticals Inc [NASDAQ: SUPN] stock has seen the most recent analyst activity on February 19, 2025, when Cantor Fitzgerald downgraded its rating to a Neutral and also revised its price target to $36 from $57. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on January 06, 2025, and set its price target to $57. On September 11, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $36 on the stock. Jefferies upgraded its rating to Buy for this stock on April 13, 2021, and upped its price target to $40. In a note dated June 16, 2020, Piper Sandler upgraded an Overweight rating on this stock and boosted its target price from $25 to $31.
Supernus Pharmaceuticals Inc [SUPN] stock has fluctuated between $25.53 and $40.28 over the past year. Currently, Wall Street analysts expect the stock to reach $38 within the next 12 months. Supernus Pharmaceuticals Inc [NASDAQ: SUPN] shares were valued at $31.17 at the most recent close of the market. An investor can expect a potential return of 21.91% based on the average SUPN price forecast.
Analyzing the SUPN fundamentals
Supernus Pharmaceuticals Inc [NASDAQ:SUPN] reported sales of 661.82M for the trailing twelve months, which represents a growth of 5.99%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.12%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.11%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.08 and Total Capital is 0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 30.84 points at the first support level, and at 30.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.71, and for the 2nd resistance point, it is at 32.24.
Ratios To Look Out For
For context, Supernus Pharmaceuticals Inc’s Current Ratio is 2.35. As well, the Quick Ratio is 2.16, while the Cash Ratio is 0.24. Considering the valuation of this stock, the price to sales ratio is 2.63, the price to book ratio is 1.68 and price to earnings (TTM) ratio is 23.64.
Transactions by insiders
Recent insider trading involved Rubin Jonathan, SVP, Chief Medical Officer, that happened on Feb 21 ’25 when 927.0 shares were sold. Sr. VP of IP, CSO, Bhatt Padmanabh P. completed a deal on Feb 04 ’25 to sell 9477.0 shares. Meanwhile, Sr. VP of IP, CSO Bhatt Padmanabh P. sold 2573.0 shares on Jan 27 ’25.
